On Long Island, the number of people getting diagnosed with HIV remained relatively flat in 2023, compared to 2022.

Sheryl Lee Ralph reflects on founding the DIVA Foundation and says her advocacy was driven by doing what was right.

The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

What does it take to integrate siloed HIV programming into wider primary health systems? Abt Global’s Lawrence Kahindi ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

BAKERSFIELD. CALIF, (KERO) — Kern County Public Health officials and HIV testing clinics address the increasing HIV cases in ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.